The United Kingdom and the United States have signed a key bilateral deal that will keep zero levies on British medicine shipments being sold in the US market.
The Terms of the Deal
Under the terms of the agreement, the UK has committed to boost spending on pharmaceuticals through the public health system. This pledge secures that duties on these vital exports will stay at nothing for a period of three years.
This development comes after earlier threats to hike import taxes on branded drug imports, with increases discussed as high as 100%.
"This deal between the United Kingdom bolsters the global environment for innovative medicines and establishes long-overdue balance to transatlantic medicine commerce," a statement noted.
Trade Impact
Medicines represent one of the UK's largest exports to the America, which is clearly the largest destination for leading British pharmaceutical firms.
Trade data indicate that in the one-year period to the end of the third quarter, the UK sold medicines worth billions to the US. This amount made up nearly one-fifth of total UK exports in that timeframe.
"This deal safeguards work, increases funding and paves the way for the UK to establish itself as a global hub for life sciences," the Business and Trade Secretary remarked.
Key NHS Changes
The deal involves several specific commitments from the United Kingdom:
- Higher Cost Ceiling: The UK will raise the price threshold at which it considers new treatments to be unaffordable by twenty-five percent.
- Higher Drug Budget: There is a goal to raise total NHS spending on drugs from 0.3 percent of Gross Domestic Product to 0.6% over the following ten-year period.
- Refund Ceiling: The percentage manufacturers must pay back to the NHS to stay within budget will be restricted at 15%. Last year, refunds exceeded twenty percent.
Industry Background
This agreement comes amid a ongoing dispute between the sector and the ministers over spending levels and approval rates.
These tensions were intensified by arguments that US consumers were paying several times more for the equivalent treatments than patients in the Britain and the EU.
In recent months, several significant drug company projects in the UK have been halted or abandoned, while multi-billion-dollar investments have been directed toward American operations.
One official publicly accepted that the NHS must increase expenditure on treatments, noting that its spending on drugs had decreased as a percentage of its resources over the past decade.
